文献速递新发突发、热带与寄生虫病

新型恶性疟原虫快速诊断试验在hrp2/3基因缺失广泛地区的性能

Performance of a Novel Plasmodium falciparum Rapid Diagnostic Test in Areas of Widespread hrp2/3 Gene Deletion.
PubMed 文献 · Clin Infect Dis · 2026-01-01

在埃塞俄比亚两个卫生中心开展横断面研究,纳入1004名参与者,以显微镜和巢式PCR为参考标准,比较新型单线HRP2/PfLDH快速诊断试验与对照试验的性能。该地区80%的恶性疟原虫感染存在hrp2或hrp3缺失,新型RDT灵敏度为77.4%、特异度为96%,优于HRP2-only对照(55.9%、56.8%),与三线对照的77.7%灵敏度相当。

要点

  • 新型RDT在hrp2/3缺失率80%的地区灵敏度77.4%、特异度96%。
  • HRP2-only对照RDT灵敏度分别为55.9%和56.8%,低于新型RDT。
  • 新型RDT与三线RDT灵敏度77.7%相当,可检测更宽抗原浓度范围。

核心结论

  • 单线、易判读的新型疟疾RDT优于常规HRP2-only RDT,在hrp2/3缺失高流行区有提升疟疾诊断的潜力。

研究设计与样本

  • 在埃塞俄比亚两个卫生中心开展的横断面研究,纳入1004名研究参与者。
  • 以显微镜检查和巢式聚合酶链反应(PCR)为参考标准,评估新型RDT与对照RDT。
  • 同时进行恶性疟原虫hrp2和hrp3基因分型及HRP2与PfLDH抗原定量。

主要发现

  • 研究地点80%的恶性疟原虫感染显示hrp2或hrp3缺失。
  • 新型RDT灵敏度为77.4%、特异度为96%。
  • HRP2-only对照Bioline™ Malaria Ag Pf灵敏度为55.9%,Bioline™ Malaria Ag Pf/Pv灵敏度为56.8%。
  • 三线Bioline™ Malaria Ag Pf/Pf/Pv RDT(检测HRP2、PfLDH和PvLDH)灵敏度为77.7%,新型RDT与其性能相当。
  • 新型RDT在更宽的HRP2和PfLDH抗原浓度范围内检测到恶性疟原虫病例。

关键数值与推荐

  • 新型RDT:灵敏度77.4%,特异度96%。
  • Bioline™ Malaria Ag Pf:灵敏度55.9%。
  • Bioline™ Malaria Ag Pf/Pv:灵敏度56.8%。
  • Bioline™ Malaria Ag Pf/Pf/Pv:灵敏度77.7%。

临床怎么用

  • 在hrp2/3基因缺失高流行区,新型单线HRP2/PfLDH RDT较HRP2-only RDT可提高恶性疟原虫检出。
  • 该新型RDT性能与三线HRP2/PfLDH/PvLDH RDT相当,且判读更简便。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rapid diagnostic tests (RDTs) have improved malaria diagnosis; however, the emergence of hrp2/3 gene deletions threatens the reliability of HRP2-based RDTs. This study evaluated the diagnostic performance of a novel RDT detecting both HRP2 and PfLDH in a single test line. METHOD: A cross-sectional study was conducted at two health centers in Ethiopia, recruiting 1004 study participants. Blood samples were tested using the novel and comparator RDTs, using microscopy and nested polymerase chain reaction (PCR) as the reference standards. Plasmodium falciparum hrp2 and hrp3 genotyping and HRP2 and P. falciparum lactate dehydrogenase (PfLDH) antigen quantification were also conducted. RESULTS: In this study setting, characterized by 80% of P. falciparum infections showing hrp2 or hrp3 deletion, the novel RDT showed a sensitivity of 77.4% and a specificity of 96%, surpassing the HRP2-only comparators Bioline™ Malaria Ag Pf (55.9%) and Bioline™ Malaria Ag Pf/Pv (56.8%). Its performance was comparable to the three-line Bioline™ Malaria Ag Pf/Pf/Pv RDT, which detects HRP2, PfLDH, and PvLDH, at 77.7% sensitivity. Additionally, the novel RDT exhibited the ability to detect P. falciparum cases across a broader range of HRP2 and PfLDH antigen concentrations compared to the comparator RDTs. CONCLUSIONS: The single-line, easy-to-interpret index malaria RDT outperforms conventional HRP2-only RDTs, making it a promising tool for enhancing malaria diagnosis in regions with high hrp2/3 deletion prevalence. Clinical Trial Registration. The study is registered on ClinicalTrials.gov ID NCT05286359.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mandefro A, Ding XC, Farge J, et al. Performance of a Novel Plasmodium falciparum Rapid Diagnostic Test in Areas of Widespread hrp2/3 Gene Deletion. Clin Infect Dis. 2026. PMID: 40274531. doi:10.1093/cid/ciaf212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。